Design Therapeutics (DSGN) Equity Ratio (2020 - 2026)

Design Therapeutics' Equity Ratio history runs 7 years deep, the most recent figure standing at 0.95 for Q1 2026.

• In Q1 2026, Equity Ratio fell 1.41% year-over-year to 0.95; the TTM figure through Mar 2026 stood at 0.95 (down 1.41% YoY), while the FY2025 annual figure was 0.94, down 2.18% from the prior year.
• Equity Ratio came in at 0.95 for Q1 2026 at Design Therapeutics, up from 0.94 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2022 to a low of 0.94 in Q4 2025.
• A 5-year average of 0.96 and a median of 0.96 in 2025 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio grew 1.75% in 2024 and dropped 2.26% in 2025, its largest moves.
• Design Therapeutics' Equity Ratio stood at 0.96 in 2022, then fell by 0.08% to 0.96 in 2023, then gained by 0.17% to 0.96 in 2024, then dropped by 2.18% to 0.94 in 2025, then advanced by 0.72% to 0.95 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.95, 0.94, and 0.94 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison